超声造影与增强CT评估肝细胞癌经动脉化疗栓塞治疗后残留肿瘤的Meta分析
该Meta分析纳入11项研究共421例患者491个结节,直接比较超声造影与增强CT评估肝细胞癌经动脉化疗栓塞治疗后残留肿瘤的诊断性能;超声造影敏感度和阴性预测值显著高于增强CT(均P<.001),增强CT特异度和阳性预测值显著高于超声造影(均P<.05)。
要点
- 超声造影敏感度0.97、阴性预测值0.90,高于增强CT的0.72和0.51,均P<.001。
- 增强CT特异度0.99、阳性预测值1.00,高于超声造影的0.86和0.97,均P<.05。
- 超声造影汇总SROC曲线下面积0.9875,增强CT为0.9239。
核心结论
- 超声造影敏感度和阴性预测值优于增强CT,是排除经动脉化疗栓塞治疗后残留肿瘤的有效方法。
- 增强CT特异度高于超声造影,是识别残留肿瘤的有效方法。
研究设计与样本
- 研究类型为Meta分析,检索PubMed、Embase、Cochrane图书馆和中国知网至2017年4月30日。
- 共纳入11项研究,包括421例患者和491个结节。
- 计算并比较超声造影与增强CT的汇总敏感度、特异度、阳性预测值、阴性预测值、阳性似然比、阴性似然比、诊断比值比和汇总受试者工作特征曲线。
诊断标准与关键数值
- 超声造影敏感度0.97(95%CI 0.95-0.99),增强CT敏感度0.72(95%CI 0.67-0.76),超声造影显著更高(P<.001)。
- 超声造影特异度0.86(95%CI 0.74-0.94),增强CT特异度0.99(95%CI 0.95-1.00),增强CT显著更高(P<.05)。
- 超声造影阳性预测值0.97(95%CI 0.95-0.99),增强CT阳性预测值1.00(95%CI 0.98-1.00),增强CT显著更高(P<.05)。
- 超声造影阴性预测值0.90(95%CI 0.83-0.95),增强CT阴性预测值0.51(95%CI 0.44-0.58),超声造影显著更高(P<.001)。
- 超声造影阳性似然比7.79(95%CI 4.73-12.82),增强CT阳性似然比12.50(95%CI 5.74-27.20);超声造影阴性似然比0.05(95%CI 0.03-0.09),增强CT阴性似然比0.35(95%CI 0.26-0.48)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study reviewed the literature to directly evaluate the diagnostic performance of contrast-enhanced ultrasonography (CEUS) versus contrast-enhanced computed tomography (CECT) for assessing residual tumors of hepatocellular carcinoma treated with transarterial chemoembolization.
METHODS: PubMed, Embase, the Cochrane Library, and the China National Knowledge Infrastructure were searched through April 30, 2017. The pooled sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristic curve were calculated and compared to examine the diagnostic performance of CEUS versus CECT.
RESULTS: A total of 11 studies, including 421 patients and 491 nodules were analyzed. The pooled diagnostic performances of CEUS versus CECT were as follows: (1) sensitivity (95% confidence interval), 0.97 (0.95-0.99) versus 0.72 (0.67-0.76); (2) specificity, 0.86 (0.74-0.94) versus 0.99 (0.95-1.00); (3) positive predictive value, 0.97 (0.95-0.99) versus 1.00 (0.98-1.00); (4) negative predictive value, 0.90 (0.83-0.95) versus 0.51 (0.44-0.58); (5) positive likelihood ratio, 7.79 (4.73-12.82) versus 12.50 (5.74-27.20); (6) negative likelihood ratio, 0.05 (0.03-0.09) versus 0.35 (0.26-0.48); (7) diagnostic odds ratio, 150.56 (57.03-397.49) versus 35.54 (14.89-84.83); and (8) area under the summary receiver operating characteristic curve, 0.9875 versus 0.9239. The sensitivity and negative predictive value of CEUS were significantly higher than those of CECT (both P < .001). The specificity and positive predictive value of CECT were significantly higher than those of CEUS (both P < .05).
CONCLUSIONS: Contrast-enhanced US, with better sensitivity and negative predictive value versus CECT, was an effective method for exclusion of residual tumors after transarterial chemoembolization. Contrast-enhanced CT, with higher specificity than CEUS, is a valid approach for identifying residual tumors.
引用
- Zhong J, Su Z, Zhang Y, et al. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis. J Ultrasound Med. 2018. PMID: 29380404. doi:10.1002/jum.14534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。